JG Chemicals delivered its strongest quarterly performance to date in Q1FY27, reporting a consolidated net profit after tax (PAT) of ₹261 million, a 59.1% year-on-year increase from ₹164 million in Q1FY26. The surge was driven by robust volume growth across end-user applications, particularly in the tyre sector, and improved operating leverage that expanded the EBITDA margin to 11.50% from 10.64% previously. This marks a new all-time high for quarterly revenue, EBITDA, and PAT for the zinc oxide manufacturer.

The Board of Directors approved the unaudited financial results on August 8, 2026, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Revenue from operations climbed 44.8% year-on-year to ₹3,157 million, while earnings per share (basic and diluted) rose to ₹6.40 per share from ₹4.03. The company’s total comprehensive income attributable to owners increased to ₹285 million.

Financial Highlights

EBITDA grew by 56.5% to ₹363 million, reflecting disciplined cost management despite higher raw material consumption. Finance costs remained negligible at ₹1 million. Other income declined slightly to ₹27 million from ₹34 million in the prior year quarter but contributed positively to total income, which stood at ₹3,184 million.

Operational Efficiency

The expansion in margins was aided by favorable demand conditions and scale efficiencies. While total expenses rose 42.3% to ₹2,821 million, this was lower than the revenue growth rate, indicating improved operational leverage. Depreciation and amortization expenses decreased marginally to ₹12 million. The company maintained strong cash flows, with net worth increasing to ₹5,510 million as of June 30, 2026, up from ₹5,235 million in FY26.

What the Numbers Show

The divergence between revenue growth (44.8%) and EBITDA growth (56.5%) signals significant operating leverage. The EBITDA margin improvement of 86 basis points to 11.50% suggests that JG Chemicals is successfully passing on cost pressures or benefiting from better product mix realization. With PAT margins expanding by 75 basis points to 8.27%, the company demonstrates robust bottom-line resilience. This performance outpaces the broader industry trends, supported by its dominant market position in India’s zinc recycling sector.

Strategic Expansion: Dahej Project

A key forward-looking development is the progress of the greenfield facility at Dahej, Gujarat. Civil works are in advanced stages, and equipment installation has commenced. The project, funded entirely through internal accruals with an investment of ₹100 crore, aims to add 40,000 MTPA of capacity. Commissioning is targeted for Q3FY27. This facility is strategic for diversifying into higher-margin non-rubber applications such as ceramics, pharmaceuticals, and agriculture, aiming to increase non-rubber revenue contribution from 15% to 30% over the next few years.

Market Position and Diversification

JG Chemicals continues to strengthen its moat through technological differentiation and customer relationships. The company serves 9 out of the top 10 global tyre manufacturers and holds a ~31% market share in India as of March 2025. Recent product launches include "LabPure" Zinc Oxide for analytical reagent grade applications and "JG-ZRA," a curing package for non-tyre rubber sectors. The inauguration of the R&D center at Naidupeta further supports innovation, enabling the production of over 90 specialized grades of zinc oxide. The subsidiary BDJ Oxides’ Naidupeta plant remains the only IATF-approved ZnO facility globally, reinforcing quality credentials for pharma and automotive clients.

JG Chemicals announced the sudden and untimely demise of Ashok Bhandari, an Independent Director on its Board, on August 3, 2026. The loss marks the end of a tenure that began on June 30, 2022, during which Bhandari served as a member of several critical governance committees, including the Audit Committee, Nomination and Remuneration Committee, Corporate Social Responsibility Committee, and Risk Management Committee. His passing creates an immediate vacancy in these oversight roles, necessitating a replacement to maintain statutory compliance and board balance.

The company notified the National Stock Exchange of India Ltd (NSE) and the Bombay Stock Exchange (BSE) pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure was made in accordance with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026, dated January 30, 2026. Swati Poddar, Company Secretary and Compliance Officer, signed the intimation, confirming that Bhandari’s membership in all aforementioned committees ceased with effect from August 3, 2026.

Committee Vacancies

Bhandari’s role extended beyond general board oversight; he was integral to the company’s compliance and strategic governance structures. The following table outlines the committees from which he has vacated his seat:

The Board of Directors expressed deep condolences to the bereaved family, citing Bhandari’s valuable guidance and significant role in the company’s strategic growth. As an Independent Director, his presence was crucial for ensuring unbiased oversight of management decisions and protecting shareholder interests.

Regulatory Compliance and Next Steps

The announcement includes Annexure A, detailing the particulars of the change as required under Schedule III of the Listing Regulations. The document confirms the reason for cessation as "Death" and lists the date of cessation as August 3, 2026. No brief profile or relationship disclosures were applicable for this specific filing, as per regulatory norms for such events.

The company must now initiate the process to appoint a new Independent Director to fill the vacancy. This appointment will require approval from the Nomination and Remuneration Committee and subsequent ratification by shareholders at the next general meeting, ensuring continuity in the board’s composition and committee mandates. Until a successor is appointed, the remaining members of the respective committees will continue to function, subject to regulatory requirements regarding quorum and independence ratios.